Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
Public ClinicalTrials.gov record NCT00875238. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Predicting Adverse Cardiac Events in Breast Cancer Therapy (PACE in Breast Cancer)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for increased risk of cardiac effects. PURPOSE: This clinical trial is studying side effects involving the heart in women with breast cancer receiving doxorubicin and trastuzumab.
Study identification
- NCT ID
- NCT00875238
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 133 participants
Conditions and interventions
Interventions
- trastuzumab Biological
- doxorubicin hydrochloride Drug
- polymorphism analysis Genetic
- laboratory biomarker analysis Other
- questionnaire administration Other
- assessment of therapy complications Procedure
- magnetic resonance imaging Procedure
Biological · Drug · Genetic + 2 more
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2008
- Primary completion
- Feb 28, 2015
- Completion
- Feb 28, 2015
- Last update posted
- Feb 18, 2018
2008 – 2015
United States locations
- U.S. sites
- 4
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Louisville James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| Vanderbilt Heart One Hundred Oaks | Nashville | Tennessee | 37204 | — |
| MBCCOP - Meharry Medical College - Nashville | Nashville | Tennessee | 37208 | — |
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232-6838 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00875238, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 18, 2018 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00875238 live on ClinicalTrials.gov.